Calamos Advisors LLC Has $26.31 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Calamos Advisors LLC raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 234,785 shares of the biopharmaceutical company's stock after acquiring an additional 2,514 shares during the quarter. Calamos Advisors LLC's holdings in Gilead Sciences were worth $26,308,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Gilead Sciences during the 1st quarter worth approximately $25,000. Goodman Advisory Group LLC acquired a new stake in Gilead Sciences during the 1st quarter worth $29,000. Annis Gardner Whiting Capital Advisors LLC grew its holdings in Gilead Sciences by 158.8% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 216 shares during the period. Synergy Investment Management LLC acquired a new stake in Gilead Sciences during the 4th quarter worth $40,000. Finally, Lee Danner & Bass Inc. acquired a new stake in Gilead Sciences during the 4th quarter worth $41,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded down $0.24 during mid-day trading on Friday, reaching $111.28. 4,039,811 shares of the company were exchanged, compared to its average volume of 7,706,267. The company's 50-day simple moving average is $107.02 and its 200-day simple moving average is $104.02. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. The stock has a market capitalization of $138.42 billion, a P/E ratio of 23.43, a P/E/G ratio of 0.72 and a beta of 0.29. Gilead Sciences, Inc. has a twelve month low of $66.34 and a twelve month high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business's revenue for the quarter was down .3% compared to the same quarter last year. During the same period last year, the business posted ($1.32) earnings per share. As a group, research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were issued a $0.79 dividend. The ex-dividend date was Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.84%. Gilead Sciences's dividend payout ratio is presently 66.53%.

Insider Buying and Selling at Gilead Sciences

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $110.42, for a total value of $1,104,200.00. Following the completion of the transaction, the chief executive officer owned 620,268 shares of the company's stock, valued at $68,489,992.56. The trade was a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $110.17, for a total value of $275,425.00. Following the completion of the transaction, the chief financial officer directly owned 165,110 shares of the company's stock, valued at approximately $18,190,168.70. This trade represents a 1.49% decrease in their position. The disclosure for this sale can be found here. Insiders sold 58,500 shares of company stock valued at $6,340,745 in the last three months. Corporate insiders own 0.27% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Morgan Stanley lifted their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Oppenheimer decreased their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective for the company. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Finally, JPMorgan Chase & Co. upped their price objective on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Nine investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences has an average rating of "Moderate Buy" and an average target price of $110.55.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.